Pfizer weight reduction tablet strikes ahead as once-daily model

Sopa Photographs | Lightrocket | Getty Photographs

Pfizer on Thursday stated it’ll transfer ahead with a once-daily model of its weight reduction tablet, danuglipron, after it noticed “encouraging” information in an ongoing early-stage trial.

The corporate evaluated a number of once-daily formulations of the drug and recognized one with “essentially the most favorable profile.” Pfizer stated it plans to behavior research in the second one part of the 12 months to spot the perfect dose of the drug.

Pfizer is considered one of a number of drugmakers racing to win a slice of the marketplace for a extremely in style magnificence of weight reduction and diabetes medication referred to as GLP-1 agonists. Some analysts be expecting the business to be value more or less $100 billion via the tip of the last decade. 

Stocks of the corporate rose greater than 3% in premarket buying and selling Thursday.

Pfizer in December discontinued a twice-daily model of danuglipron after sufferers had hassle tolerating the drug in a mid-stage find out about. On the time, the pharmaceutical large stated section one trial information at the once-daily model would “tell a trail ahead.” 

However traders were pessimistic concerning the corporate’s doable within the GLP-1 house because it scrapped a special once-daily tablet in June 2023. The ones had been amongst a string of setbacks Pfizer confronted final 12 months on best of the fast decline of its Covid industry, which battered its inventory. 

Nonetheless, Pfizer has different experimental medication in previous levels of construction, together with one for weight problems. The corporate has no longer disclosed how the ones therapies will paintings. 

Pfizer believes GLP-1s are handiest “scratching the outside of what we can see in weight problems,” CEO Albert Bourla stated all through a convention in June. 

Pfizer’s danuglipron is a GLP-1 that promotes weight reduction in the similar manner as Novo Nordisk’s injection Wegovy and diabetes remedy Ozempic. The medicine mimic a unmarried hormone produced within the intestine referred to as GLP-1, which indicators to the mind when an individual is complete.

Injections from Novo Nordisk and Eli Lilly have soared in call for over the past 12 months regardless of their hefty value tags and restricted insurance policy. 

The pair – together with Pfizer and different drugmakers – were racing to expand oral variations which can be extra handy for sufferers to take and more uncomplicated to fabricate, which might lend a hand alleviate provide shortages within the U.S. 

Pfizer has no longer dominated out obtaining or partnering with a smaller weight problems drugmaker. 

Bourla informed newshounds at a convention in January that it used to be not likely the corporate would purchase an weight problems remedy in later-stage construction, particularly as the corporate makes a speciality of slicing prices. 

However he stated Pfizer used to be on the lookout for doable licensing offers or earlier-stage weight reduction medication. 

Pfizer’s replace on danuglipron comes days after the corporate stated it’s looking for a successor to its Leader Clinical Officer Mikael Dolsten, who will step down after greater than 15 years on the drugmaker. Dolsten performed a an important position in growing Pfizer’s Covid vaccine.

Leave a Reply

Your email address will not be published. Required fields are marked *